Welcome to our dedicated page for Tevogen Bio SEC filings (Ticker: TVGNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Complex biotech filings often bury the details that matter鈥攖rial endpoints, patent cliffs, or insider share moves. For Tevogen Bio, whose CD8+ T-cell pipeline and AI-driven discovery model add extra layers of science and risk, those disclosures stretch across hundreds of pages. If finding the cash-runway note in a 10-K or the latest executive stock sale feels overwhelming, you are not alone.
Stock Titan鈥檚 platform brings every Tevogen Bio SEC document into one place and translates jargon into clear takeaways. Our AI-powered summaries highlight what the annual report 10-K means for pipeline milestones, flag material 8-K events within minutes of hitting EDGAR, and decode quarterly earnings report 10-Q filing numbers into trend charts. AG真人官方-time alerts track Form 4 insider transactions so you can see buying or selling as it happens, while side-by-side comparisons of proxy statement executive compensation link leadership incentives to clinical goals.
Use the page below to explore Tevogen Bio insider trading Form 4 transactions, review the company鈥檚 Form 4 insider transactions real-time feed, and access Tevogen Bio SEC filings explained simply. Whether you need Tevogen Bio earnings report filing analysis for cash-burn insight, Tevogen Bio annual report 10-K simplified for pipeline risk factors, Tevogen Bio proxy statement executive compensation data, or Tevogen Bio 8-K material events explained, our tools reduce research hours to minutes. Understanding Tevogen Bio SEC documents with AI has never been easier鈥攕o you can focus on decisions, not document digging.
Schedule 13D/A Amendment 1 shows Tevogen Bio Holdings Inc. (TVGNW) CEO Dr. Ryan H. Saadi now beneficially owns 125,008,376 shares, equal to 64.5 % of the 193.7 M shares outstanding. He holds sole voting power over 124.8 M shares and sole dispositive power over 97.5 M shares; 193.9 k shares are jointly held with his spouse.
The filing reflects two noteworthy changes since the original 13D: (1) on 27 Jun 2025 the Company granted Saadi 8.0 M restricted shares (鈮�4 % of current float) that carry immediate voting rights but vest in four equal tranches starting seven years after grant, with accelerated vesting on death or disability; and (2) Saadi sold 1,438,206 shares on 9 Jun 2025 in the open market at a VWAP of $1.23.
No other transactions were reported in the prior 60 days. Apart from the potential dilution from the new award and the limited insider sale (鈮�1 % of his stake), the amendment does not signal strategic changes. Saadi remains the controlling shareholder, aligning management incentives with long-term equity performance.
FAQ
What is the current stock price of Tevogen Bio (TVGNW)?
